Evidence map›Paper›PMID 38150215›Full record

ArticleJAMA surgery2024

Magnetic Seed vs Guidewire Breast Cancer Localization With Magnetic Lymph Node Detection: A Randomized Clinical Trial.

Eirini Pantiora, Allan Jazrawi, Abdi-Fatah Hersi, Shahin Abdsaleh, Hanna Ahlstedt, Eva Molnar, Fredrik Wärnberg, Staffan Eriksson, Andreas Karakatsanis

Open access · greenAbstract read
In one paragraph

Article in JAMA surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. SCOUTCancers · 2025
    Article
  9. Therapy of early breast cancer: current status and perspectives.Archives of gynecology and obstetrics · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Eirini PantioraDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Allan JazrawiCenter for Clinical Research, Department of Surgical Sciences, Uppsala University, Västerås, Sweden.
Abdi-Fatah HersiCenter for Clinical Research, Department of Surgical Sciences, Uppsala University, Västerås, Sweden.
Shahin AbdsalehDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Hanna AhlstedtDepartment of Breast Radiology, Division of Radiology, Västmanlands County Hospital, Västerås, Sweden.
Eva MolnarDepartment for Breast Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Fredrik WärnbergDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Staffan ErikssonCenter for Clinical Research, Department of Surgical Sciences, Uppsala University, Västerås, Sweden.
Andreas KarakatsanisDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Västmanlands sjukhus Västerås · SEUppsala University · SESahlgrenska University Hospital · SEUniversity of Gothenburg · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Guidewires have been the standard for breast lesion localization but pose operative and logistic challenges. Paramagnetic seeds have shown promising results, but to the authors' knowledge, no randomized comparison has been performed. Objective: To determine whether the combination of a paramagnetic seed and superparamagnetic iron oxide (SPIO) is equivalent to guidewire and SPIO for breast cancer localization and sentinel lymph node detection (SLND). Design, Setting, and Participants: This was a phase 3, pragmatic, equivalence, 2-arm, open-label, randomized clinical trial conducted at 3 university and/or community hospitals in Sweden from May 2018 to May 2022. Included in the study were patients with early breast cancer planned for breast conservation and SLND. Study data were analyzed July to November 2022. Interventions: Participants were randomly assigned 1:1 to a paramagnetic seed or a guidewire. All patients underwent SLND with SPIO. Main Outcomes and Measures: Re-excision rate and resection ratio (defined as actual resection volume / optimal resection volume). Results: A total of 426 women (median [IQR] age, 65 [56-71] years; median [IQR] tumor size, 11 [8-15] mm) were included in the study. The re-excision rate was 2.90% (95% CI, 1.60%-4.80%), and the median (IQR) resection ratio was 1.96 (1.15-3.44). No differences were found between the guidewire and the seed in re-excisions (6 of 211 [2.84%] vs 6 of 209 [2.87%]; difference, -0.03%; 95% CI, -3.20% to 3.20%; P = .99) or resection ratio (median, 1.93; IQR, 1.18-3.43 vs median, 2.01; IQR, 1.11-3.47; P = .70). Overall SLN detection was 98.6% (95% CI, 97.1%-99.4%) with no differences between arms (203 of 207 [98.1%] vs 204 of 206 [99.0%]; difference, -0.9%; 95% CI, -3.6% to 1.8%; P = .72). More failed localizations occurred with the guidewire (21 of 208 [10.1%] vs 4 of 215 [1.9%]; difference, 8.2%; 95% CI, 3.3%-13.2%; P < .001). Median (IQR) time to specimen excision was shorter for the seed (15 [10-22] minutes vs 18 [12-30] minutes; P = .01), as was the total operative time (69 [56-86] minutes vs 75.5 [59-101] minutes; P = .03). The experience of surgeons, radiologists, and surgical coordinators was better with the seed. Conclusions and Relevance: The combination of SPIO and a paramagnetic seed performed comparably with SPIO and guidewire for breast cancer conserving surgery and resulted in more successful localizations, shorter operative times, and better experience. Trial Registration: ISRCTN.org Identifier: ISRCTN11914537.

Indexed as

Breast NeoplasmsFerric CompoundsAgedFemaleHumansLymphatic MetastasisLymph NodesMagnetic PhenomenaSentinel Lymph Node BiopsyFerric Compoundsferric oxide

Identifiers

PMID38150215
PMCPMC10753436
OpenAlexW4390265467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.